Cargando…
Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness
The availability of erythropoiesis-stimulating agents (ESAs) has revolutionized the treatment of anaemia in patients with chronic kidney disease. However, maintaining patients at haemoglobin (Hb) levels that are both safe and provide maximal benefit is a continuing challenge in the field. Based on e...
Autores principales: | de Francisco, Angel L. M., Stenvinkel, Peter, Vaulont, Sophie |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638546/ https://www.ncbi.nlm.nih.gov/pubmed/19461856 http://dx.doi.org/10.1093/ndtplus/sfn176 |
Ejemplares similares
-
Haemoglobin and anaemia in the SMART study
por: Mocroft, A, et al.
Publicado: (2010) -
Inflammation as a target for improving health in chronic kidney disease
por: Stenvinkel, Peter
Publicado: (2010) -
Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia
por: Tshilolo, L., et al.
Publicado: (2012) -
Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019) -
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)